Balance Sheet StrengthZero reported debt and an improving equity base give Mizuho Medy durable financial flexibility, lowering bankruptcy and refinancing risk. This conservatism supports investment in product development or capacity, secures dividend ability, and cushions the business through cyclical swings over the next 2–6 months.

High ProfitabilitySustained net margins near 30% reflect strong cost structure and pricing in core IVD reagents, enabling internal funding for R&D, dividends, and selective M&A. High margin durability helps absorb volume volatility and supports consistent free cash generation over a multi‑quarter horizon.

Recurring Consumables Business ModelA consumables-driven model (reagents used per test) produces repeatable revenue streams tied to clinical testing volumes, enhancing predictability and customer stickiness. This structural revenue base supports steady demand and margin visibility across quarters, benefiting cash flow and product cross-sell.

Bears Say

Weaker Cash Conversion In 2025A decline in operating cash flow and cash conversion in 2025 reduces free cash flow flexibility relative to earnings, tightening funding for capex, dividends or new product rollouts. If conversion weakness persists, it elevates volatility of available cash for strategic initiatives in the coming quarters.

Declining Returns On EquityA multi-year decline in ROE signals waning earnings power versus prior peaks, potentially from pricing, mix, or competitive pressures. Lower profitability on equity constrains long-term shareholder returns and suggests management must improve growth or efficiency to restore prior performance.

Choppy Revenue Growth / Profit NormalizationModest, uneven revenue growth and normalization of margins from 2022 highs indicate demand or mix headwinds. This variability reduces top‑line visibility and makes future margin recovery uncertain, limiting the company's ability to sustainably expand operating leverage over the next several quarters.

4595 FAQ

What was Mizuho Medy Co., Ltd.’s price range in the past 12 months?

Mizuho Medy Co., Ltd. lowest stock price was ¥1341.00 and its highest was ¥1930.00 in the past 12 months.

What is Mizuho Medy Co., Ltd.’s market cap?

Mizuho Medy Co., Ltd.’s market cap is ¥35.49B.

When is Mizuho Medy Co., Ltd.’s upcoming earnings report date?

Mizuho Medy Co., Ltd.’s upcoming earnings report date is May 08, 2026 which is in 63 days.

How were Mizuho Medy Co., Ltd.’s earnings last quarter?

Mizuho Medy Co., Ltd. released its earnings results on Feb 13, 2026. The company reported ¥96.42 earnings per share for the quarter, beating the consensus estimate of N/A by ¥96.42.

Is Mizuho Medy Co., Ltd. overvalued?

According to Wall Street analysts Mizuho Medy Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Mizuho Medy Co., Ltd. pay dividends?

Mizuho Medy Co., Ltd. pays a Semiannually dividend of ¥45 which represents an annual dividend yield of 6.29%. See more information on Mizuho Medy Co., Ltd. dividends here

What is Mizuho Medy Co., Ltd.’s EPS estimate?

Mizuho Medy Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Mizuho Medy Co., Ltd. have?

Mizuho Medy Co., Ltd. has 19,051,200 shares outstanding.

What happened to Mizuho Medy Co., Ltd.’s price movement after its last earnings report?

Mizuho Medy Co., Ltd. reported an EPS of ¥96.42 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.715%.

Which hedge fund is a major shareholder of Mizuho Medy Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4595

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Mizuho Medy Co., Ltd.

Mizuho Medy Co.,Ltd. researches and develops, manufactures, and sells in-vitro diagnostic products and related scientific and technical information services primarily in Japan. The company provides immunoassay test products, such as influenza virus kits; RS virus and human metapneumovirus antigen test kits; streptococcus pneumoniae antigen and legionella antigen test kits; mycoplasma pneumoniae antigen test kits; adenovirus antigen test kits; rotavirus and adenovirus antigen test kits; norovirus antigen test kits; group a streptococcal antigen test kits; pregnancy test kits; ovulation test kits; and fecal occult blood test kits. It also offers gene analysis instrument; SARS-CoV-2 detection kits; and mycoplasma pneumoniae nucleic acid kits. In addition, the company engages in import and export activities. It also operates in the United States, Belgium, Finland, Netherlands, Taiwan, Thailand, etc. The company was incorporated in 1977 and is headquartered in Tosu, Japan.